and function. In identifying risk factors for valve degeneration, including some that are potentially modifiable, they also provide, at a minimum, hypothesis-generating data for additional studies.
COMPARISON WITH PRIOR STUDIES
This article should be viewed as complementary to a recently published article by the same group 5 that reports their follow-up of 209 patients undergoing bioprosthetic AVR from 2002 to 2004 for whom 10-year echocardiographic follow-up was available. Because the dates overlap those of the current study (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) , there is likely some overlap in the patient groups. Although the former article focuses on structural valve degeneration (SVD) and this article addresses hemodynamic valve degeneration, the distinction is blurred in that both terms are defined as describing very similar hemodynamic and structural abnormalities. Differences between the definitions used for hemodynamic valve degeneration and SVD in the 2 articles from the Laval group 4, 6 are minor. It is noted that patients with pannus and thrombus were excluded in the current study, with pannus remaining in their SVD article and thrombus not specifically excluded. The earlier study reports a late-term prevalence of subclinical SVD of 30% and clinical (ie, at least moderateto-severe hemodynamic disturbance) SVD of 6% which is similar to the 39% 10-year incidence of hemodynamic valve degeneration in the current study. Body mass index, age, and use of the Mitroflow valve (stented bovine pericardium) were independent predictors of SVD in the multivariable analysis in the early study, whereas in the current study, female sex, warfarin use, stented versus stentless valve (with subanalysis by valve brand not provided), and bovine pericardial versus porcine valve were associated with the late risk of valve degeneration. It is difficult to tell what percentage of patients in the early study had Mitroflow valves, but they accounted for 8% of the valves in the later study, and it is possible that these valves accounted for the higher risk for pericardial valves. It is not surprising that the results in the 2 studies are similar given the similarities in the study group and study design. Both studies confirm a prevalence of valvular degeneration that is higher than might be expected. In aggregate, the 2 studies emphasize the importance of meticulous imaging and Doppler evaluation of prostheses during follow-up, because structural and hemodynamic changes could easily be overlooked during superficial evaluation.
OTHER CONSIDERATIONS Absence of Valve Area Data
Although the study methods indicate that the reduction in effective orifice area was required as supportive to increased gradients for the diagnosis of hemodynamic valve degeneration, no effective orifice area data are provided. Later in the article, the authors state that they did not have stroke volume data but these should be available as a derivative of continuity equation calculations. As the authors note, valve gradients are flow-and heart rate-dependent, and changes in effective orifice area as identified in the article by Rodriguez-Gabella et al 6 would have been supportive. A simpler method of correcting for changes in stroke volume, the
Valve Thrombosis
Although it is appealing to exclude thrombus and pannus in studies of SVD, the recent Makkar study has taught us that it is often impossible to exclude these conditions on transthoracic echocardiograms, hence the important role for transesophageal echocardiography and computed tomography. 1 Color paucity on transvalvular color Doppler evaluation has been reported to provide a clue to valve thrombus, but transesophageal echocardiography and computed tomography are important confirmatory tests. 7 Salaun et al 4 do not disclose how many patients were excluded for thrombus or pannus, and no representative images are provided to illustrate their diagnostic imaging or Doppler criteria. It would be interesting to know how many patients underwent transesophageal echocardiography and computed tomography, in particular those with hemodynamically significant dysfunction. Furthermore, if they imply that there were no patients with thrombus, ie, no exclusions for thrombus, this would be at odds with the Makkar et al study 1 and would warrant discussion. Although exclusion of these conditions does not detract from the overall message of the study that structural valve disease is more common than we traditionally thought, it does impact the conclusion that warfarin might be replaced with non-vitamin K antagonist oral anticoagulants in patients with aortic bioprostheses. Although the discussion of vitamin K metabolism and cusp integrity is thought-provoking, it must be acknowledged that the conditions for which anticoagulation was prescribed may be important confounders and, in the Makkar et al study of presumptive valve thrombosis, warfarin not only reversed valve dysfunction but also appeared to be protective from incident dysfunction.
Valve Specificity of the Findings
A number of studies have demonstrated important differences in the rate of SVD across valve platforms. Thus, pending additional confirmation, the findings must be interpreted as preliminary and perhaps specific to the mix of valves used at Laval over this period that included 8% Mitroflow valves and 21% stentless valves. Confirmatory studies would be important to allow valve-specific subanalysis as was addressed in the Rodriguez-Gabella et al study 6 that identified Mitroflow valve use as an independent multivariate predictor of clinical SVD and stentless prosthesis use as a univariate predictor of subclinical SVD.
Trial Specific or Clinical Interpretations?
It would be useful to know whether the echocardiographic Doppler parameters reported are those generated for routine clinical reporting or specifically for purposes of the study. If the data were obtained from clinical reports, what was the laboratory protocol for irregular heart rhythms because these were not excluded? Was variability analysis performed on a subset of the study group for Doppler and imaging parameters? Were single beats or the average of multiple beats used? Were multiple windows used to ensure that the maximum transaortic gradients were accurately captured?
IMPORTANCE OF THE STUDY
The most important clinical implication from this study is a reminder that prosthetic valve degeneration is relatively common but easily overlooked without regular and systematic clinical follow-up including echocardiography. This provides an argument for more frequent surveillance echocardiograms as has been recommended in the European 8 but not the American Heart Association/American College of Cardiology 3 guidelines for valvular heart disease. These results also support the requirement for at least annual echocardiographic evaluation in surgical and transcatheter aortic valve trials and registries, as well. The identification of potentially modifiable risk factors is provocative and is hypothesis-generating for additional trials. Based on the observations of this study, additional trials should be large enough in scale and long enough in duration for the variables found to be significant in either the univariate or multivariate analysis to be studied.
